|
|
|
|
Novelos ends development of lung cancer drug
Less than a month after reporting it had poor results from a lung cancer drug, Novelos Therapeutics Inc.has decided to end the development of the drug as an adjunct to current lung cancer chemotherapy drugs. Novelos ends development of lung cancer drug.<...
|
|
|
ChildrenEURs Hospital and Genocea Biosciences partner
Genocea Biosciences Inc.and Childrens Hospital Boston have announced an agreement under which Cambridge-based Genocea is licensing a portfolio of Streptococcus pneumoniae antigens developed in a collaboration among Genocea, Childrens and the Seattle-based...
|
|
|
Alkermes launches Phase 1 trial for chronic pain drug candidate
Alkermes Inc.has launched an early stage drug trial for a potential treatment for side effects of opiod use for patients will chronic pain. The Waltham-based company will conduct a Phase 1 study on ALKS 37, a drug target to treat constipation brought on by...
|
|
|
ALS Therapy Institute pairs with N.J. biotech
Cambridge-based ALS Therapy Institute has teamed up with a New Jersey biotech to test several small-molecule compounds that have the potential to slow or stop the progression of Amyotrophic Lateral Sclerosis (ALS), commonly called Lou Gehrigs disease.ALS TDI...
|
|
|
2010 Women to Watch: GSK's Michelle Dipp promotes new drug development
Michelle Dipp, VP, Center of Excellence for External Drug Discovery at GlaxoSmithKline, is a 2010 Mass High Tech Women to Watch honoree.2010 Women to Watch: GSK's Michelle Dipp promotes new drug development.
|
|
|
2010 Women to Watch: Aura Bioscience's Elisabet de los Pinos combines entrepreneurship and management skills
Elisabet de los Pinos, CEO of Aura Biosciences Inc., is a 2010 Mass High Tech Women to Watch honoree.She is the co-inventor of technologies behind two U.S. 2010 Women to Watch: Aura Bioscience's Elisabet de los Pinos combines entrepreneurship and...
|
|
|
Biotech, drug R&D grew in 2009
Research and development investment by pharmaceutical and biotechnology companies defied the recession in 2009, growing by more than 2 percent over the 2008 total, according to the Pharmaceutical Research and Manufacturers of America (PhRMA) and life sciences...
|
|
|
Alkermes shares jump amid FDA response to diabetes drug
Alkermes Inc.shares popped Monday on news that federal regulators responded positively to a new diabetes-drug application filed by the Waltham-based biotechnology firm and its development partners, Amylin Pharmaceuticals Inc. and Eli Lilly and Co.
|
|
|
Pescatello named president of New England Biotech Association
At its annual meeting, the New England Biotech Association (NEBA) elected Paul Pescatello as its president for 2010.A board member since NEBAs founding, Pescatello serves as director of Connecticut United for Research Excellence (CURE). The new president...
|
|
|
Connecticut backs diagnostics firm HistoRx
Connecticut Innovations has announced a $1.5 million loan to HistoRx Inc., a New Haven-based firm working on diagnostic solutions for cancer treatment.HistoRx licensed its core technology from Yale University and is developing and commercializing a...
|
